Global Markets for Enzyme Inhibitors
The global market for enzyme inhibitors was valued at $104.4 billion in 2010 and reached nearly $104.6 billion in 2011. This market is expected to rise at a compound annual growth rate (CAGR) of 4% and reach nearly $127.4 billion by 2016.
The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.
The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on “Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.),” which was given an award of excellence.
During the forecast period, enzyme-inhibiting drugs are projected to be introduced for new indications including asthma and chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, hepatitis C and intermittent claudication.
Recent withdrawals of products in the COX-2 inhibitor class along with recent and future introductions of novel products in other classes will rearrange the market share of categories in the enzyme inhibitor sector. Overall, the market for products included in this report is expected to show an average annual growth rate (AAGR) of approximately 6.7% from 2005 to 2011, increasing from $29.2 billion to $43.1 billion.
Of all the inhibitor categories, COX-2 and PDE4 will see increases in revenue share for the period 2005 to 2011. Cox-2 inhibitors' share will grow from 12.7% to 18.9%, while PDE4 inhibitors will increase from zero in 2005 to 3.6% in 2011.